AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8365284
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg aerosolized pentamidine once monthly
Trial: 8365284
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aerosolized pentamidine twice monthly
Trial: 8365284
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (300 mg) prophylaxis
Trial: 3534025
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of a cream or lotion containing 2% hydroquinone and 0.05% to 0.1% retinoic acid (tretinoin)
Trial: 3534025
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of topical sunscreen preparations
Trial: 3534025
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of oral contraceptives and other agents that promote skin pigmentation
Trial: 27488098
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (fresh oranges and orange juice)
Trial: 25322597
Drug: Endoscopic sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sinus surgery (ESS) based comprehensive treatment
Trial: 23106412
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) twice a week
Trial: 23106412
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation therapy with docetaxel (DOC) at a dose of 10 mg/m(2) once a week
Trial: 21968659
Drug: 2.5% THPE-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% THPE-containing cream
Trial: 16566965
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 2% lignocaine gel with 0.05% chlorhexidine gluconate (group 1, n = 72)
Trial: 16566965
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 2% lignocaine and aqueous gel mixture (group 2, n = 69)
Trial: 10623705
Drug: Adjuvant active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine, three weekly intradermal vaccine injections of 10^7 irradiated autologous tumor cells and 10^7 BCG organisms for the first two injections
Trial: 10623705
Drug: Adjuvant active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-BCG vaccine
Trial: 1326404
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg sumatriptan sc
Trial: 3493795
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at varying rates (60 to 200 micrograms kg‐1 min‐1)
Trial: 23988639
Drug: Telmisartan treatment
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan treatment among patients with low eGFR
Trial: 19076931
Drug: anti-IgE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-IgE treatment
Trial: 16752286
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate cement augmentation
Trial: 14997032
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose p38 MAPK inhibitor (BIRB 796 BS) 600 mg
Trial: 14997032
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose p38 MAPK inhibitor (BIRB 796 BS) 50 mg
Trial: 9412209
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g once daily parenterally
Trial: 9412209
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g 8 hourly for a minimum of 7 days
Trial: 8314099
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (individual and family counseling, support group participation, and ad hoc consultation)
Trial: 30130147
Drug: L-Dex measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Dex measurement using the L-Dex U400 device
Trial: 30130147
Drug: Normative values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normative values for L-Dex
Trial: 21863338
Drug: Placebo gels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gels
Trial: 21863338
Drug: All gels
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All gels (including VivaGel(®) and placebo)
Trial: 20199360
Drug: 24-hour 10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour 10-mg controlled-release vaginal dinoprostone pessary
Trial: 20199360
Drug: Repeat doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat doses of 2 mg vaginal dinoprostone gel
Trial: 15660542
Drug: Saline group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline group - catheters flushed with 3 mL of normal saline 0.9% after each catheter use
Trial: 15660542
Drug: Heparin group
RxNorm normalized name: Heparin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin group - catheters flushed with 3 mL of 100-U/mL heparin in normal saline 0.9% after each catheter use
Trial: 15660542
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - catheters not flushed following drug administration
Trial: 10483544
Drug: Gel containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel containing 0.5 mg of dinoprostone placed intracervically every four hours
Trial: 10483544
Drug: Polymer insert
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymer insert containing 10 mg of dinoprostone intravaginally
Trial: 6349926
Drug: Daily vitamin
RxNorm normalized name: Daily Vitamin Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vitamin supplementation
Trial: 24500308
Drug: Paricalcitol-centred therapy
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol-centred therapy (IV and oral)
Trial: 24500308
Drug: Paricalcitol-centred therapy
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paricalcitol-centred therapy
Trial: 24500308
Drug: Cinacalcet-centred therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet-centred therapy
Trial: 19669013
Drug: 1.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg‐1 of 0.375% bupivacaine associated with 150 (1/4)g of clonidine (2 mL)
Trial: 19669013
Drug: 1.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg‐1 of 0.375% bupivacaine associated with NS (2 mL)
Trial: 11288210
Drug: Nebulized epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized epinephrine (0.5 mg of 0.1% solution)
Trial: 11288210
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (2.5 mg)
Trial: 8196140
Drug: rhIL-1ra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-1ra (100 mg loading dose followed by 1.0 or 2.0 mg/kg per hour continuous infusion)
Trial: 30795802
Drug: intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal ranibizumab therapy
Trial: 11013194
Drug: Hydroxyapatite implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite implant
Trial: 11013194
Drug: Acrylic implant
RxNorm normalized name: acrylate
DrugBank: Acrylic Acid (DB02579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acrylic implant
Trial: 12026534
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy (hemodialysis and kidney transplantation)
Trial: 2683758
Drug: Anti-Tac monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-Tac monoclonal antibody (20 mg, administered intravenously daily for 10 days)
Trial: 2683758
Drug: Anti-Tac monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-Tac monoclonal antibody
Trial: 1089438
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of phenol into the lumbar sympathetic chain
Trial: 1089438
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of local anaesthetic subcutaneously (Control)
Trial: 31177752
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) 3 g/day for 6 months
Trial: 31177752
Drug: Perilla oil
RxNorm normalized name: Perilla frutescens leaf oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilla oil (PO) 3 g/day for 6 months
Trial: 31177752
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil mixed with linseed oil (FLO) 3 g/day for 6 months
Trial: 28486976
Drug: Thromboprophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboprophylaxis with low-molecular-weight heparin (LMWH) at a dose of 85 IU/kg once daily during asparaginase courses of ALL treatment
Trial: 28486976
Drug: No thromboprophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thromboprophylaxis (standard of care) during asparaginase courses of ALL treatment
Trial: 25439084
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + usual treatment
Trial: 22097092
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg kg(‐1))
Trial: 22097092
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (1 microg kg(‐1))
Trial: 19857084
Drug: GoChi (Lycium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GoChi (Lycium barbarum fruit juice) at 120 mL/day for 30 days
Trial: 9519518
Drug: Information leaflet
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information leaflet (in patients treated with antibiotics)
Trial: 9519518
Drug: No leaflet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No leaflet (control, in patients treated with antibiotics)
Trial: 8287585
Drug: Naloxone (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2.4 mg)
Trial: 8287585
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water (1 ml)
Trial: 3816314
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol via inhalation aids (InspirEase, Aerochamber, Aerosol Bag)
Trial: 3816314
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol via MDI mouthpiece
Trial: 3816314
Drug: Placebo via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via inhalation aids
Trial: 26767384
Drug: Nerve growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve growth factor (0.5 mg as eye drops for 10 days)
Trial: 23886739
Drug: 66 mg/mL
RxNorm normalized name: pectin 66 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 66 mg/mL iodine
Trial: 23886739
Drug: 100 mg/mL
RxNorm normalized name: urea 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL iodine
Trial: 23886739
Drug: >133 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >133 mg/mL iodine
Trial: 20433339
Drug: Traditional dysarthria
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional dysarthria therapy (TRAD)
Trial: 18458698
Drug: Esmolol 1
RxNorm normalized name: esmolol 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1 mg/kg followed by 250 µg/(kg·min)
Trial: 10443336
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk supplement (1 litre daily for 4 weeks)
Trial: 8527268
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg orally with grapefruit juice
Trial: 8527268
Drug: Nifedipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 2.5 mg intravenously with grapefruit juice
Trial: 2104736
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg orally
Trial: 8527268
Drug: Nifedipine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 2.5 mg intravenously
Trial: 340305
Drug: Clomipramine (Anafranil)
RxNorm normalized name: clomipramine Oral Capsule [Anafranil]
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine (Anafranil) plus behaviour therapy
Trial: 340305
Drug: Clomipramine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine plus simulated behaviour therapy
Trial: 7621388
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy alone
Trial: 25245625
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily for 4 weeks
Trial: 25245625
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily for 8 weeks
Trial: 19130489
Drug: 20-week treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-week treatment trial
Trial: 11004136
Drug: Individualized dietary
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dietary counseling aiming for fat intake of 30% to 35% of daily energy, saturated/monounsaturated/polyunsaturated fatty acid ratio of 1:1:1, cholesterol intake of <200 mg/d
Trial: 1519481
Drug: Interferon-alpha (IFN‐alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day for 28 days (open trial)
Trial: 1519481
Drug: Interferon-alpha (IFN‐alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN‐alpha) at a dose of 3.0 x 10(6) IU/day (randomized trial)
Trial: 1519481
Drug: Interferon-alpha (IFN‐alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN‐alpha) at doses of 3.0 x 10(6), 1.0 x 10(6) or 0.3 x 10(6) IU/day (randomized trial)
Trial: 29691233
Drug: 50 μmol
RxNorm normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μmol oral BSE‐SFN daily for 28 days
Trial: 29691233
Drug: 100 μmol
RxNorm normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μmol oral BSE‐SFN daily for 28 days
Trial: 29691233
Drug: 200 μmol
RxNorm normalized name: MOL-4239
DrugBank: MOL-4239 (DB16051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μmol oral BSE‐SFN daily for 28 days
Trial: 24744162
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 6 months (control group)
Trial: 24744162
Drug: UFT (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (300 mg/m²) plus leucovorin (75 mg/day) for 18 months (study group)
Trial: 22172982
Drug: Concurrent visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent visual task during text composition
Trial: 20451668
Drug: Continuation phase
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation phase cognitive therapy (C-CT)
Trial: 2491361
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg once daily
Trial: 2614884
Drug: ONO‐3708 (thromboxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO‐3708 (thromboxane A2 antagonist)
Trial: 18615332
Drug: Betahistine 16
RxNorm normalized name: betahistine 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 16 mg tid
Trial: 18615332
Drug: Betahistine 24
RxNorm normalized name: betahistine 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine 24 mg bid
Trial: 17989709
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without stem cell transplant
Trial: 15950639
Drug: Single-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose (SD) protocol for GnRH antagonist (cetrorelix)
Trial: 15950639
Drug: Multiple-dose (MD)
RxNorm normalized name: miconazole nitrate Topical Solution [Nail MD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose (MD) protocol for GnRH antagonist (cetrorelix)
Trial: 15950639
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol (LP) for GnRH agonist (buserelin)
Trial: 7579007
Drug: epalrestat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epalrestat (150 mg/day, 50 mg tid, po)
Trial: 7579007
Drug: placebo (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (9 mg/day, 3 mg tid, po)
Trial: 7806684
Drug: Haloperidol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (all doses)
Trial: 27884499
Drug: Closed chain
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed chain exercises (CC)
Trial: 19679384
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) recipe (Panax, 520 mg; Astragalus membranaceous Bunge, 520 mg; Masnetitum, 840 mg; Ostrea gigas Thumb, 470 mg; Thinleaf Milkwort Root Radix Polygalae, 450 mg; Os Draconis, 470 mg) administered as a diet supplement for 60 days.
Trial: 17565930
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin ointment administered twice daily for 5 days every 4 weeks
Trial: 8985764
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no mupirocin treatment)
Trial: 14614669
Drug: Intranasal mupirocin
RxNorm normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal mupirocin ointment
Trial: 9670693
Drug: Acupuncture treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatments in addition to standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Trial: 9670693
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (allopurinol, NSAIDs, glucocorticosteroids)
Trial: 2929157
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (chemo and radiotherapy)
Trial: 26948366
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with procarbazine, lomustine, vincristine (PCV)
Trial: 26948366
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with temozolomide
Trial: 26948366
Drug: Delaying radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delaying radiotherapy and treatment with chemotherapy only
Trial: 25422394
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three interventions